To develop an in vivo model for studying the role of the p53 tumor suppressor in skin carcinogenesis, a murine p53 172H mutant (equivalent to human p53 175H ) was expressed in the epidermis of transgenic mice, utilizing a targeting vector based on the human keratin 1 gene (HK1.p53 m ). HK1.p53 m mice developed normally and did not exhibit an obvious epidermal phenotype or develop spontaneous tumors. However, these mice demonstrated an increased susceptibility to a two-stage chemical carcinogenesis protocol, with the rate of formation and number of papillomas being dramatically increased as compared to non-transgenic controls. The majority of papillomas in control mice regressed after termination of 12-O-tetradecanoylphorbol-13-acetate (TPA) treatment, whereas p53 m papillomas progressed to carcinomas and metastases. In addition, more advanced malignancy, i.e., undierentiated spindle cell carcinomas, were exclusively observed in p53 m mice. Increased bromodeoxyuridine (BrdU) labeling, accompanied by decreased expression of p21, was observed in HK1.p53 m papillomas. In situ examination of centrosomes in HK1.p53 m papillomas also revealed marked abnormalities, with 75% of the cells containing 53 centrosomes/cell, whereas centrosome numbers in papillomas from control animals remained normal. These data suggest that the accelerated tumorigenesis observed in chemically-treated p53 m mice is most likely due to increased genomic instability resulting from an inhibition of G1 arrest and abnormal ampli®cation of centrosomes.
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Introduction
The p53 tumor suppressor gene is the most frequently mutated gene in human cancers (Greenblatt et al., 1994) and in numerous experimental models (Jacks, 1996) . Conventionally, mutations resulting in the loss of function of the wildtype p53 gene (wt p53 or p53 +/+ ) are thought to play a causal role in tumorigenesis (Greenblatt et al., 1994; Jacks, 1996) , hence the p53 knockout (p53 7/7 ) mouse succumbs to a variety of spontaneous tumors, the most frequent of which are lymphomas, osteosarcomas and soft tissue sarcomas (Donehower et al., 1992) . Although p53 mutations also frequently occur in skin cancers (Brash et al., 1991; Moles et al., 1993; Nakazawa et al., 1994) , it is not clear at which stage p53 loss is critical for skin tumor development. In the murine two-stage skin carcinogenesis model (DiGiovanni, 1992) , i.e., initiation with dimethylbenz[a]anthracene (DMBA) followed by promotion with tetradecanoyl-phorbol-13-acetate (TPA), p53 mutations have been consistently detected in carcinomas but not papillomas (Burns et al., 1991; Ruggeri et al., 1991) , suggesting that mutation of the p53 gene occurs as a relatively late event. Subjecting p53 7/7 mice to a similar chemical carcinogenesis protocol also identi®ed a late role for p53 loss, evident by a dramatic increase in malignant conversion in p53 7/7 versus hemizygous (p53
) or p53 +/+ genotypes (Kemp et al., 1993) . Conversely, in human skin cancer, particularly on sun exposed areas, typical UV-B induced p53 mutations were detected in early pathological stages, such as actinic keratosis (Ziegler et al., 1994) . Additional support for p53 loss in initiating events was revealed by a decreased number of apoptotic`sunburn' cells in p53 7/7 mouse skin, as compared to control skin after exposure to genotoxic doses of UV-irradiation (Ziegler et al., 1994) , since reduction in the apoptotic response to UV-induced DNA damage would potentially allow initiated cells to survive.
In an attempt to gain further insight into the stagespeci®c eect of p53 loss in skin carcinogenesis in vivo, we initially set up series mating experiments between p53 7/7 mice and transgenic mice expressing epidermally-targeted v-ras Ha (Greenhalgh et al., 1993a) , v-fos (Greenhalgh et al., 1993b) , and transforming growth factor a (TGFa) (Dominey et al., 1993) . Unexpectedly, an inhibition of both spontaneous and TPA-promoted papilloma formation was observed in all crosses into the p53 7/7 background (Greenhalgh et al., 1996) . Similarly, when p53 7/7 mice were exposed to a twostage chemical carcinogenesis protocol, they also exhibited a surprising resistance to early stage carcinogenesis (papillomatogenesis), in spite of eventually exhibiting a higher rate of malignant conversion (Kemp et al., 1993) . Thus, it appears that the epidermis, which is frequently exposed to environmental carcinogens, possesses additional defense mechanisms to compensate for p53 loss in the early stages of skin carcinogenesis.
The unexpected resistance of p53 7/7 mice to early stages of skin carcinogenesis hampered attempts to investigate the mechanistic role of p53 loss in malignant conversion and metastasis of skin tumors, since these mice routinely died from internal malignancies at 5 ± 7 months of age (Kemp et al., 1993; Greenhalgh et al., 1996) . To overcome this problem, we attempted to generate a transgenic mouse model in which the epidermis would exhibit a functional knockout of p53, as a result of expression of a dominant negative form of p53. One of the best characterized mutants which exhibits a dominant negative eect in vitro (Kern et al., 1992; Zhang et al., 1993; Ory et al., 1994) , is p53 175 R?H , a human cancer`hot spot' (Greenblatt et al., 1994; Dittmer et al., 1993) . In vitro studies have also shown that this p53 mutation exerts a putative`gain-of-function' in that it is able to augment cell transformation in the absence of wt p53 (Dittmer et al., 1993) . Therefore, utilizing an epidermal-speci®c vector based on the human keratin 1(HK1) gene (Chung et al., 1994) , we targeted expression of the mouse p53 172H mutation, which is equivalent to human p53 175H . Although HK1.p53 m mice developed normally and failed to develop spontaneous tumors, they did exhibit increased susceptibility to chemical carcinogenesis with greatly accelerated benign papilloma formation, malignant conversion and metastasis, culminating in advanced, undierentiated spindle cell carcinomas. HK1.p53 m papillomas showed increased bromodeoxyuridine (BrdU) labeling, which was accompanied by decreased expression of p21, suggesting a failure in G1 arrest. In addition, HK1.p53 m papillomas, in contrast to wt p53 tumors, contained an abnormal number of centrosomes. Thus, accelerated chemical carcinogenesis in HK1.p53 m mice appears to be due to increased genomic instability.
Results

Generation and identi®cation of HK1.p53 m mice
To target expression of the p53 m to the epidermis, we used a truncated human keratin 1 promoter (HK1), which directs expression of transgenes in both basal and suprabasal layers of the epidermis. The construction and characterization of this vector have been described previously (Greenhalgh et al., 1993a,b) . A point mutation at codon 172, which changes an arginine residue to histidine, was introduced to the mouse p53 cDNA. This mutant p53 cDNA was subcloned to the HK1 targeting vector (Figure 1) , and the puri®ed HK1.p53 m transgene was then microinjected into mouse embryos obtained from mating ICR females to strain FVB males. After birth, transgenic mice were con®rmed by PCR analysis of their tail DNA using primers #5 and #6 (Figure 1 ), which are speci®c for the ®rst intron of the HK1 vector (Greenhalgh et al., 1993a,b) Construction of HK1.p53 m transgene. The p53 m cDNA was generated by using an overlapping PCR technique. Overlapping primers #1 and #2 were used to introduce a codon 172 Arg?His mutation (CGC?CAC). Primers #3 and #4 were utilized to generate the full length p53 m cDNA. The p53 m cDNA was ligated into XmaI and ClaI sites of the HK1 vector. Transgenic mice were con®rmed by PCR analysis of their tail DNA using primers #5 and #6, which are speci®c for the ®rst intron of the HK1 vector. Primers #7 and #8 were used to generate a PCR fragment that serves as a template of a riboprobe speci®c for the HK1 3' untranslated region nucleus and cytoplasm of cells located throughout the suprabasal layers of the epidermis, as well as in *30% of basal cells (Figure 2a ). Wildtype p53 protein was not detected in control epidermis Figure 2a . RNase protection assays were used to quantitate transgene expression levels in neonatal epidermis. The HK1.p53 m transgene, detected by a probe speci®c to the HK1 3' non-coding region, was exclusively expressed in the epidermis of transgenic mice (Figure 2b ). To compare expression levels of p53 m with that of the endogenous p53 gene, a probe that recognizes both the wildtype and mutant p53 transcripts was used. Ratios of the p53 m transgene versus the wt p53 gene were calculated to be 4 : 1 for line B6183, 6 : 1 for line B6192, and 8 : 1 for line B6405 (Figure 2b ). Based on in vitro studies, which previously documented the potent dominant negative activity of this p53 m (Zhang et al., 1993) , we anticipated that expression levels of p21, an inhibitor of cyclin-dependent kinases and a critical target for mediating wt p53-induced G1 arrest (Harper et al., 1993; el-Deiry et al., 1993) would be decreased in HK1.p53 m epidermis. Unexpectedly, expression levels of p21 were slightly elevated in the epidermis of HK1.p53 m compared to the non-transgenic control ( Figure 2b ).
HK1.p53
m mice exhibit increased susceptibility to DMBA-TPA induced papilloma formation and malignant conversion Since HK1.p53 m mice did not develop spontaneous tumors, we assessed their susceptibility to a chemical carcinogenesis protocol. DMBA was utilized as an initiator followed by repeated promotion with TPA. In total, 30 mice in each group from both HK1.p53 m mice and non-transgenic control mice were treated. In contrast to previous results obtained with p53 7/7 mice (Kemp et al., 1993) , HK1.p53 m mice exhibited an accelerated formation and increased number of papillomas (Figure 3a, b) , with the earliest appearing by 1 ± 4 weeks of TPA promotion, compared to 6 weeks for control p53 +/+ siblings. By 8 weeks of TPA promotion, all of HK1.p53 m mice developed papillomas, whereas only 70% of the non-transgenic control group developed papillomas by 10 weeks, with 30% of these mice remaining tumor-free at the termination of this study (50 weeks). Additionally, HK1.p53 m mice averaged 12.1+4.2 papillomas/mouse at the end of the promotion stage (12 weeks), a threefold increase as compared to control siblings (4.3+2.6 papillomas/ mouse). Furthermore, p53 m papillomas persisted, i.e. exhibited autonomous growth, unlike tumors in control mice, which have a tendency to regress after the TPA treatments have been terminated (Figure 3b ). These chemical carcinogenesis experiments clearly demonstrate an unexpected ability of p53 m to in¯uence early stages of papillomatogenesis, without any evidence for the compensatory pathway previously observed in p53 7/7 mice (Kemp et al., 1993; Greenhalgh et al., 1996) .
To determine at which stage p53 m may in¯uence skin carcinogenesis in vivo, DMBA and TPA were applied separately to HK1.p53 m mice. Topical application of TPA alone does not induce tumor formation in normal mice (DiGiovanni, 1992; Jhappen et al., 1994) . However, when TPA is applied to mice expressing m transcripts relative to that of wt p53 transcripts in non-transgenic epidermis, and calculated to be 4 : 1 for line B6183, 6 : 1 for line B6192 and 8 : 1 for line B6405. p21 expression levels were slightly elevated in transgenic epidermis compared to the non-transgenic epidermis activated ras Ha in the epidermis, papillomas appear with rapid kinetics (Greenhalgh et al., 1996) . Although HK1.p53 m mice were treated with TPA for over 6 month, they failed to develop papillomas, indicating that treatment with DMBA is required to provide the initiation event. If epidermal cells only contain an initiation event, such as c-ras
Ha mutations, typically induced by a sub-carcinogenic dose of DMBA (DiGiovanni, 1992), they will not develop tumors unless a constitutive promoting stimulus, e.g. TPAtreatment, is provided (DiGiovanni, 1992; Jhappen et al., 1994) . HK1.p53 m mice also failed to develop tumors with a single DMBA application, ruling out the role of p53 m as a constitutive tumor promoter. Thus, it appears that treatment with both DMBA and TPA is required before p53 m can in¯uence papillomatogenesis. Once the promotion stage begins, p53 m mediated events occur very quickly, with overt tumors appearing soon after the initiation of TPA treatments (Figure 3a) . HK1.p53 m papillomas converted to squamous cell carcinomas (SCC) as early as 20 weeks after initiating TPA promotion (Figures 3c, 4a) . By 40 weeks, when the ®rst well-dierentiated SCC appeared in control mice (Figure 3c ), all HK1.p53 m mice were already exhibiting advanced malignancies, varying from poorly dierentiated SCC (Figure 4a ), to invasive, undifferentiated spindle cell carcinomas (SPCC) Figure 4c , both of which metastasized to inguinal lymph nodes (Figures 4b,d ) and lungs. In contrast, only 30% of control siblings developed well-dierentiated SCC by 50 weeks, and neither SPCC nor metastases were observed.
Analysis of chemically-induced tumors for endogenous c-ras
Ha and p53 mutations Previous chemical carcinogenesis experiments have associated p53 loss with the malignant conversion stage (Ruggeri et al., 1991; Burns et al., 1991) , therefore p53 m tumors were analysed for mutations in the endogenous p53 gene. In total, 10 carcinomas and 2 metastases were analysed and all were devoid of spontaneous mutations in the endogenous p53 gene (data not shown). This result suggests that p53 m is able to augment neoplasia in cooperation with ras Ha , even in the presence of wt p53.
Expression of the HK1.p53 m transgene, endogenous p53 and p21 in p53 m tumors
To determine whether the HK1.p53 m transgene was causally involved in accelerating chemically-induced tumor formation and progression, RNase protection assays were used to detect transgene expression in tumors. HK1.p53 m transgene expression was detected exclusively in papillomas from HK1.p53 m mice ( Figure  5 ). Both p53 +/+ and p53 m papillomas showed elevated endogenous p53 expression compared to a normal adult mouse epidermis (Figure 5) , which was con®rmed Figure 6a ) was threefold higher than that of control papillomas (20+3.5, n=6, Figure 6b ). We also examined the rate of apoptosis in both HK1.p53 m and non-transgenic tumors, but it was not altered (data not shown). Thus, consistent with decreased levels of p21, p53 m papillomas appear to be impaired in their ability to arrest in G1.
p53 m papillomas exhibit abnormal centrosome ampli®cation
The role of p53 in maintaining genomic stability is best documented in a G1 checkpoint, via activation of p21 (Wahl et al., 1997; O'connor, 1997) , however other studies suggest that p53 may also be involved in a spindle checkpoint (Cross et al., 1995; Fukasawa et al., 1996; Fukasawa and Vande Woude, 1997) . Therefore, we used in situ confocal microscopy to examine centrosomes in early stage papillomas. Because centrosomes duplicate only once during the cell cycle, excessive duplication, as indicated by multiple centrosomes in the cytoplasm, would result in unequal segregation of chromosomes (Brinkley, 1985) . Strikingly, a signi®cantly abnormal centrosome pro®le was observed in p53 m papillomas, with up to 30% of the cells containing three centrosomes, and 45% 54, whereas cells containing a normal pro®le of one or two centrosomes/cell only comprised 12% and 13% of the total, respectively (Figure 7) . In contrast, all of the cells in non-transgenic papillomas possessed normal centrosome numbers, with 70% of cells containing one centrosome and 30% containing two centrosomes ( Figure 7 ).
Discussion
Expression of p53 m alone does not produce an epidermal phenotype or predispose to spontaneous tumor development, but increases sensitivity to chemical carcinogenesis
Previous attempts to utilize p53
7/7 mice to investigate the mechanistic role of p53 loss in malignant conversion and metastasis of skin tumors have been restricted by the relative resistance of p53 7/7 epidermis to carcinogenesis, compared to other tissues, with death usually occurring at 5 ± 7 months of age from internal malignancies such as lymphomas or sarcomas (Kemp et al., 1993; Greenhalgh et al., 1996) . We attempted to circumvent this problem by producing a functional knockout of p53 in the epidermis via expression of a potent dominant negative p53 mutant (p53
172H
). Three independent transgenic lines were established, and although expression levels of p53 m exceeded that of wt p53 over a range of 4 ± 8-fold, p53 m mice developed normally and failed to developed spontaneous skin tumors throughout their normal lifespan. It thus appears that the activities of this mutant are either silent, or counter-balanced by wt p53 Note that papillomas in both non-transgenic and HK1.p53 m mice showed elevated p53 expression, which was con®rmed as wt p53 by sequence analysis. However, decreased expression of p21 was only detected in HK1.p53 m papillomas Figure 6 BrdU uptake and staining. A DMBA/TPA-induced papilloma from an HK1.p53 m mouse (a) showed about a threefold increase in BrdU labeling of nuclei (yellow or green dots) over that of a non-transgenic control mouse (b). The red color is the K14 counter stain which highlights the epithelial component of papillomas. Bar represents 100 mm in normal epidermis. This is also evident by the lack of a dominant negative eect on expression levels of p21 in neonatal HK1.p53 m epidermis. Since p53 7/7 mice were resistant to early stages of skin carcinogenesis, we were surprised to discover that HK1.p53 m mice were very sensitive to a DMBA-TPA chemical carcinogenesis protocol. HK1.p53 m mice not only developed papillomas more rapidly than wt p53 mice, but p53 m tumors also progressed to malignancies earlier, resulting in very aggressive, metastatic lesions. Consistent with previous reports employing DMBA initiation, all tumors possessed activated endogenous c-ras Ha mutations. Interestingly, while both p53 +/+ and p53 m papillomas showed elevated p53 expression, wt p53 expression was only able to maintain p21 expression levels in papillomas from non-transgenic control animals, whereas p53 m papillomas exhibited a signi®cant decrease in p21 expression. This is most likely due to the potent dominant negative activity of this p53 mutant protein, which previous in vitro studies have shown is attributable in part to its longer half life as compared to wt p53 (Hinds et al., 1990) . However, the decrease in expression of p21, seen exclusively in p53 m papillomas, but not in overtly normal p53 m neonatal epidermis, also suggests that p53 m is only able to exert a dominant negative eect following perturbation of the epidermis by additional genetic/ epigenetic events, i.e. those induced by DMBA initiation/TPA promotion. The exact mechanism which activates p53 m remains to be determined, however, since we were able to detect high levels of p53 m protein in neonatal epidermis, we speculate that modi®cations, e.g. those occurring at a post-translational level, may be required to induce conformational changes in p53 m before it can function as a dominant negative in early stage papillomas. Induction of genomic instability may be the primary mechanism whereby p53 m accelerates tumorigenesis
One important mechanism consistent with the propensity of p53 m papillomas to undergo a rapid tumor progression, centers on the role of p53 in maintaining genomic stability (Livingstone et al., 1992; Yin et al., 1992; Carder et al., 1993; Lee et al., 1994; Schaefer et al., 1993; Bouer et al., 1995; Donehower et al., 1995; D'Errico et al., 1997) . In this regard, genomic instability can be a consequence of the loss of p53-dependent G1 arrest via deregulation of p21 (Wahl et al., 1997; O'connor, 1997) , which would be supported by the decreased p21 levels in p53 m tumors. Although p21 knockout mice were not reported to be predisposed to develop skin cancer, two groups have recently used primary keratinocytes derived from p21 7/7 mice in an attempt to determine whether the absence of p21 may accelerate tumorigenesis. However, these two groups obtained dierent results. Missero et al. (1996) 
transduced p21
7/7 keratinocytes with a retrovirus encoding v-ras Ha , and following subcutaneous injection into nude mice, observed progression to malignant carcinomas. Using a very similar approach, Weinberg et al. (1997) reported that v-ras Ha transduced wt p21 and p21 7/7 keratinocytes formed well-dierentiated papillomas when grafted to nude mouse, without progressing to the carcinoma stage. Therefore, on the basis of these reports, it is unclear whether deregulation of p21 alone would be sucient to allow rapid progression of p53 m tumors. However, failure to arrest in G1, indicated by the increased BrdU labeling index, could certainly contribute to the accelerated rate of formation and growth of p53 m papillomas. Although the role of p53 in maintaining genomic stability via a G1 checkpoint is well established (Wahl et al., 1997; O'connor, 1997) , there are also reports suggesting that p53 is a component of a spindle checkpoint that ensures the maintenance of diploidy (Cross et al., 1995; Fukasawa et al., 1996; Fukasawa and Vande Woude, 1997) . Speci®cally, Fukasawa et al., (1996) have reported abnormal ampli®cation of centrosomes in p53 7/7 mouse embryo ®broblasts (MEFs). To determine whether p53 m would induce centrosome abnormalities in vivo, we examined centrosomes in early stage papillomas by in situ confocal microscopy. Markedly abnormal centrosome pro®les were detected in p53 m papillomas, but not in those of non-transgenic controls, suggesting that p53 m and activated c-ras Ha act synergistically to induce aberrant centrosome ampli®cation. This idea is supported by the recent observation that oncogenes such as ras, which constitutively activate the mitogen-activated protein kinase (MAPK) pathway, greatly enhance chromosome instability in p53 7/7 MEFs (Fukasawa and Vande Woude, 1997) . Consistent with our observations, genomic instability was also observed in malignant mammary tumors expressing this same p53 mutant, where aneuploid and tetraploid cells were detected (Li et al., 1997) . However, since malignant mammary tumors were examined in that study, the dierence in the number of tetraploid or aneuploid cells in transgenic tumors versus non-transgenic controls was less pronounced, due to the general increase in genomic instability at this stage of tumor progression. Our results document that abnormal centrosome ampli®cation occurred at a very early stage in p53 m tumors, prior to any overt signs of genomic instability in control tumors. Therefore, induction of genomic instability associated with centrosome abnormalities may be the primary mechanism whereby p53 m accelerates tumorigenesis in this transgenic model.
The increased sensitivity of HK1.p53 m mice to chemical carcinogenesis suggests that p53 m functions in both a dominant negative and a-gain-of-function manner On the bases of in vitro studies (Dittmer et al., 1993) and clinical observations (Crook and Vousden, 1992) , it has been suggested that tumors containing putative gain-of-function p53 mutations may have a poorer prognosis than those with loss of p53. Taken collectively, the data obtained from the present study in HK1.p53 m mice and previous studies in p53 7/7 mice (Kemp et al., 1993; Greenhalgh et al., 1996) document that this is also the case for experimentally induced skin carcinogenesis. The decreased expression levels of p21 observed in p53 m papillomas indicate that once other genetic/epigenetic events have taken place, p53 m is able to function in a potent dominant negative manner. However, if p53 m was only functionally inactivating wt p53, then we would have expected HK1.p53 m mice to exhibit a similar resistance to early stages of skin carcinogenesis, as p53 7/7 mice. The dramatic increase in sensitivity of HK1.p53 m mice to chemical carcinogenesis suggests that p53 m is providing an additional gain-of-function that mediates alternative mechanisms of carcinogenesis.
Once activated, it is unclear how this mutant p53 exerts this additional gain-of-function. In vitro studies have shown that this p53 mutant binds poorly to a consensus DNA sequence recognized by wt p53 (Kern et al., 1991) , and lacks wt p53 transactivation activity (Raycroft et al., 1991) . Therefore, if it is functioning at the transcriptional level, it may regulate dierent target genes (Chen et al., 1992) . Alternatively, p53 m may function via protein-protein interactions (Chen et al., 1994) , and given that wt p53 can physically interact with centrosomes (Blair et al., 1988; Brown et al., 1994) , it is possible that p53 m may directly in¯uence centrosome ampli®cation.
Perhaps a more plausible explanation, that would be consistent with the ability of p53 m to function in both a dominant negative and gain-of-function manner, may be provided by the recent discovery of p73, a putative tumor suppressor gene with signi®cant homology to p53 in the DNA-binding, transactivation and oligomerization domains (Kaghad et al., 1997) . Like p53, p73 can inhibit cell cycle progression by transactivating expression of p21 (Kaghad et al., 1997; Jost et al., 1997) . In addition, p73 can induce apoptosis Jost et al. (1997) . Kaghad et al. (1997) also used a yeast two-hybrid assay to demonstrate potential heterotypic interactions between p73 and p53. It remains to be determined whether p73 is expressed in the epidermis. If it is, and if its expression can compensate for the loss of p53, then this would provide a potential explanation for the paradoxical resistance of p53 7/7 epidermis to early stages of carcinogenesis. If heterotypic interactions do occur between p53 and p73 in vivo, and p53 m is able to functionally inactivate p73, as well as p53, then this could explain the apparent gain-of-function associated with increased genomic instability.
In summary, the marked increase in sensitivity of HK1.p53 m mice to chemical carcinogenesis, as compared to p53 7/7 mice, suggests that this p53 m possesses activities beyond simply inactivating wild type p53 function. However, the in¯uence of genetic background on susceptibility to carcinogenesis is well documented, and it should be emphasized that strain dierences do exist between the p53 7/7 mice used by Kemp et al., (1993) and the HK1.p53 m mice generated in this study. To ultimately determine whether this p53 m possesses a true gain-of-function activity will require the introduction of this mutation into the p53 locus by a knock-in strategy.
Materials and methods
Generation of HK1.p53 m transgenic mice
The p53 m cDNA was generated by using an overlapping PCR technique to introduce a codon 172 R?H mutation (CGC?CAC). The overlapping primers ( Figure 1 ) are: #1(forward): 5'-GACGGAGGTCGTGAGACACTGCC-CCCACCATGAGC-3', #2 (reverse): 5' ± GCTCATGG-TGGGGGCAGTGTCTCACGACCTCCGTC-3'. The distal 5' primer #3 (5' ± CGCACCGGTCCACCATGAC-TGCCATGGAGGAG-3') introduces an AgeI site; and the 3' primer #4 (5' ± CCCATCGAT TCAGTCTGAGT-CAGGCCC-3') introduces a ClaI site. The ®rst PCR was performed using the wt p53 cDNA as a template with primers #1 and #4, and #2 and #3, respectively ( Figure  1 ). The second PCR was then performed to produce the full-length p53 m cDNA by using the above PCR products as the template, and the distal 5' and 3' primers #3 and #4 (Figure 1 ). The p53 m was sequenced to con®rm that the PCR generated product was correct and then ligated into Xmal and Clal sites of the HK1 vector. The HK1.p53 m transgene was released from the pGem 7Z plasmid by digestion with EcoRI and then microinjected into mouse embryos obtained from mating ICR females to FVB males. After birth, transgenic mice were con®rmed by PCR analysis of their tail DNA using primers #5 and #6 (Figure 1 ), which are speci®c for the ®rst intron of the HK1 vector (Greenhalgh et al., 1993a,b) .
Immunohistochemistry for p53 m expression
Neonatal skin from transgenic and control mice was ®xed in 10% formalin-PBS (pH 7.4), embedded in paran and sectioned. Sections were treated with 10 mM citric acid (pH. 6.0) at 958C for 10 min for antigen retrieval, and reacted with the p53 antibody-7 (Oncogene Science, diluted 1 : 250 in 12% BSA-PBS) at room temperature for overnight. The immune complex was detected by the avidin-biotin-peroxidase complex method (Hsu et al., 1981) using Vectastain kits (Vector Lab, CA). Immune complexes were visualized with diaminobenzidine and counterstained with 1% methyl green.
RNase protection assays
Total RNA was isolated from neonatal and adult mouse epidermis, and chemically-induced tumors with RNAzol B (Tel-Test, Inc.) as previously described (Greenhalgh et al., 1996) . RNase protection assays, using the RPA II kit (Ambion, TX) and 32 P-labeled riboprobes, were performed to determine expression levels of p53 (both wt and p53 m ), the HK1.p53 m transgene, and p21, respectively. A riboprobe corresponding to a 300-bp fragment located between an internal Rsal site and the stop codon of wt p53 cDNA was utilized to recognize both the wt p53 and p53 m . A probe speci®c for the 3' non-coding region of the HK1 vector was used to detect transcripts from the HK1.p53 m transgene. The template of this probe was generated by PCR, using primers (Figure 1 ) #7 (5'-TAAGAGATG-CCCTCTGTTT-3') and #8 (5'-AAATGTCATGTGG-GTGGTGG-3'), and cloned into the T/A vector (Promega). The riboprobe for the p21 was speci®c for a 250 bp fragment from the XmaI site to the 3' end of the p21 cDNA. To normalize each RNA sample for dierences in loading, a [ 32 P]GAPDH riboprobe was included in each analysis. The intensity of protected bands was determined by densitometeric scanning of X-ray ®lms.
Chemical carcinogenesis protocol
Ten-week-old HK1.p53 m heterozygous mice and their nontransgenic littermates were divided into groups for treatments with DMBA/TPA, DMBA, and TPA, respectively. The back skin of each mouse was carefully shaved 2 days before the treatment. A sub-carcinogenic dose of DMBA (50 mg dissolved in 100 ml acetone), was applied to the shaved skin of mice in both DMBA and DMBA/TPA groups. One week after DMBA initiation, mice in the DMBA/TPA group were topically treated with 5 mg of TPA (dissolved in 50 ml acetone), once a week for 12 weeks. Mice in the TPA group received a topical application of 5 mg of TPA once a week for 60 weeks.
Tissue histology
Biopsied skins or tumors were ®xed in Carnoy's solution (chloroform/acetic acid/ethanol, 3 : 1 : 6) at 408C overnight, transferred to 95% ethanol, embedded in paran, sectioned at 6 m, and stained with hematoxylin and eosin (H&E).
Analysis of the endogenous c-ras
Ha and p53 genes for mutations
To analyse tumors for endogenous c-ras Ha mutations, cDNA from tumor RNA was generated by RT, as described above. The resultant cDNA was ampli®ed by PCR using c-ras Ha speci®c oligonucleotides (forward: 5' -GGGGCAGGAGCTCCTGGATTGGCAGCCGCT -3'; and reverse: 5'-CCTGTACTGATGGATGTCCTCGAAG-GACTT-3'), under conditions previously described (Greenhalgh et al., 1993a,b) . The PCR products were then puri®ed through a PCR puri®cation kit (Qiagen), and applied for cycle sequencing using a cycle sequencing kit (Strategene) and internal primers. Cycles were set up at 958C for 5 min, then 30 cycles of ampli®cation at 948C for 30 s, 608C for 50 s and 728C for 1 min. The ®nal extension was at 728C for 15 min.
Exons 4 to 8 of the p53 gene were ampli®ed from tumors by PCR. The PCR products were then analysed using the Mismatch II Kit (Ambion, TX), and cycle sequencing using a cycle sequencing kit (Strategene) and internal primers. The SP6 or T7-linked intron-speci®c primers for amplifying the templates for both the mismatch assays and cycle sequencing are as follows: Exon4: 5'-SP6-GAGGCATTGAAAGGT-CACACG-3', 5'-T7-GGATATCAGCCTCGAGCTCCC-3'; Exon5 ± 6: 5'-SP6-GGAACCGACTCAGCGTCTCT-3',5'-T7-GGACAGCCAGGGCTACATAGA-3'; Exon 7 ± 8 : 5'-SP6-GGAGAGAGCAAGAGGTGACTTT-3', 5'-T7-GAAGCA-GGTGGAATATCCCTACTC-3'. The oligo sequences for RNA polymerases are: 5'-TCATTTAGGTGACACTATA-3' for SP6, and 5'-GATAATACGACTCACTATA-3' for T7.
BrdU uptake and staining
Tumor-bearing mice were injected (i.p.) with BrdU 125 mg/ kg in 0.9% NaCl. The same size of DMBA/TPA-induced papillomas from HK1.p53 m and non-transgenic control mice were biopsied 1 h after the injection, ®xed and processed as previously described (Greenhalgh et al., 1996) . Sections were incubated with FITC-conjugated monoclonal antibody to BrdU (Becton-Dickenson) and a guinea-pig antiserum to mouse keratin 14 (K14), which reacts with the epithelial component of papillomas. K14 was visualized by biotinylated anti-guinea-pig IgG (Vector) and Streptavidin-Texas Red (GIBCO). The labeling index was expressed as the mean of BrdU-positive cells/mm basement membrane of the papilloma+s.d.
Apoptosis assays
Apoptosis was evaluated using a Deoxynucleotidetransferase Uridine End Labeling (TUNEL) assay with the TACS kits from Trevigen Inc. (Gaithersburg, MD). Tumors were ®xed in 10% neutral buered formalin, sectioned, and visualized by diaminobenzidine.
Centrosome localization
Frozen papillomas were sectioned to 30 mm thickness and ®xed with 3.7% formaldehyde after 2 min treatment with 0.5% triton X-100. Samples were then incubated with human autoantiserum PCM-1, that recognizes centrosomes in mammalian cells (a gift from Dr Balczon), and rabbit anti-keratin K14, which reacts with the epithelial component of papillomas, followed by incubation with FITCconjugated goat anti-human IgG and Texas Red conjugated goat anti-rabbit IgG. The sections were then visualized using a laser scanning microscope (Molecule Dynamics Inc.) Abbreviations HK1.p53 m : p53 172 R→H mutant expressed from a human keratin K1 promoter; TPA: 12-O-tetradecanoylphorbol-13-acetate; DMBA: dimethylbenz[a]anthracene; p21: or WAF1/CIP1, an inhibitor of cyclin-dependent kinases; BrdU: bromodeoxyuridine.
